Gsk earnings were $5.8B for the trailing 12 months ending Sep 30, 2026, with -21.3% growth year over year. The latest GSK earnings report on Sep 30, 2026 announced Q3 2026 earnings of $2.0B, up 252.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, GSK reported annual earnings of $7.7B, with 140% growth.
GSK past earnings growth
How has GSK's earnings growth performed historically?
On GSK's earnings call on Oct 28, 2026, Gsk (NYSE: GSK) reported Q3 2026 earnings per share (EPS) of $1.02, up 24.31% year over year. Total GSK earnings for the quarter were $2.05 billion. In the same quarter last year, Gsk's earnings per share (EPS) was $1.35.
As of the last Gsk earnings report, Gsk is currently profitable. Gsk's net profit (also called net income) for the twelve months ending Sep 30, 2026 was $5.77 billion, a 22.27% decrease year over year.
What was GSK's earnings growth in the past year?
As of Gsk's earnings date in Oct 28, 2026, Gsk's earnings has grown -21.3% year over year. This is 61.28 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 39.98%. GSK earnings in the past year totalled $5.79 billion.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.